Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis
J Invest Dermatol, 2022.
Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups.
Read publication: J Invest Dermatol
Related
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational ...
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
0 Comments